[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-354412-105":59,"doc-detail-354412-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","proteasome-inhibition-induces-a-brcaness-like-state-and-sensitises-hr-proficient-ovarian-cancer-models-to-parp-inhibitors","Proteasome inhibition induces a BRCAness-like state and sensitises HR-proficient ovarian cancer models to PARP inhibitors","","Poly (ADP-ribose) polymerase inhibitors (PARPi) benefit ovarian cancer, but roughly half of high-grade serous tumors retain intact homologous recombination repair and are classified as homologous recombination–proficient (HRP), reducing PARPi effectiveness. A drug repurposing screen tested 97 targeted agents for induction of a functional HRD-like state and PARPi sensitization in HRP models. Proteasome inhibition, especially ixazomib citrate, disrupted RAD51 recruitment, enhanced olaparib-induced DNA damage, and triggered G2/M arrest and apoptosis. Combined treatment suppressed xenograft growth and increased MHC class I expression while augmenting CD8+ T-cell–mediated killing in vitro.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/proteasome-inhibition-induces-a-brcaness-like-state-and-sensitises-hr-proficient-ovarian-cancer-models-to-parp-inhibitors/354412/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/proteasome-inhibition-induces-a-brcaness-like-state-and-sensitises-hr-proficient-ovarian-cancer-models-to-parp-inhibitors/354412.png","ImageObject",300,407,{"name":92,"@type":93},"Mary Man","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-11","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is PARP inhibitor therapy limited in HRP ovarian cancer?","Question",{"text":112,"@type":113},"Approximately half of high-grade serous ovarian cancers retain intact homologous recombination repair and are classified as HRP, which limits the clinical benefit of PARPi in this population.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What was the key finding of the drug repurposing screen?",{"text":117,"@type":113},"Proteasome inhibitors emerged as the most consistent sensitising drug class, and ixazomib citrate showed robust synergy with olaparib across multiple HRP ovarian cancer models.",{"name":119,"@type":110,"acceptedAnswer":120},"How does ixazomib citrate sensitize HRP models to PARP inhibition?",{"text":121,"@type":113},"Ixazomib citrate disrupted RAD51 recruitment to DNA damage sites without reducing RAD51 expression, inducing a functional HRD-like state that increases olaparib-induced DNA damage, leading to G2/M arrest and apoptosis.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},354412,1790193034,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},7421720224475,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","TYPE Original Research PUBLISHED 19 June 2026  \nDOI 10.3389/fimmu.2026.1828316  \nOPEN ACCESS  \nEDITED BY  \nTiezheng Hou,  \nUniversity College London, United Kingdom  \nREVIEWED BY  \nLi Xiaoyang,  \nShanghai Jiao Tong University, China Jungang Zhao,  \nZhejiang University, China Wei Yuan,  \nNantong University, China  \n*CORRESPONDENCE  \nAnyue Wu  \n[anyue_wu@163.com](anyue_wu@163.com)[ ](anyue_wu@163.com)Lihua Qiu;  \n [lilyqiulh@126.com](lilyqiulh@126.com)  \n†These authors have contributed equally to this work  \nRECEIVED 11 March 2026  \nREVISED 01 June 2026  \nACCEPTED 05 June 2026  \nPUBLISHED 19 June 2026  \nCITATION  \nHe R, Wei Y, Niu J, Huang J, Wu R, Gu K, Wu A and Qiu L (2026) Proteasome inhibition induces a BRCAness-like state and sensitises HR-proﬁcient ovarian cancer models to PARP inhibitors.  \nFront. Immunol. 17:1828316 .  \ndoi: 10.3389/fimmu.2026.1828316  \nCOPYRIGHT  \n© 2026 He, Wei, Niu, Huang, Wu, Gu, Wu and Qiu. This is an open-access article distributed under the terms of the  \nCreative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nProteasome inhibition induces a BRCAness-like state and sensitises HR-proﬁcient ovarian cancer models to PARP inhibitors  \nRuiju He 1,2†, Yingting Wei 1,2†, Jing Niu 1,2, Jinghua Huang 1,2, Ruolan Wu 1,2, Kaiyan Gu 1,2, Anyue Wu 1,2* and Lihua Qiu 1,2,3*  \n1 Department of Obstetrics and Gynaecology, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China, 2Shanghai Key Laboratory of Gynaecologic Oncology, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China, 3State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China  \nBackground: Poly (ADP-ribose) polymerase inhibitors (PARPi) have improved outcomes in ovarian cancer with homologous recombination deﬁciency (HRD) . However, approximately half of high-grade serous ovarian cancers retain intact homologous recombination repair and are c lassiﬁed as homologous recombination–proﬁcient (HRP), limiting the clinical beneﬁt of PARPi in this population. Strategies capable of pharmacologically inducing a functional HRDlike state may expand the therapeutic scope of PARPi.  \nMethods: A drug repurposing screen of 97 FDA-approved targeted agents was conducted in olaparib-insensitive HRP ovarian cancer cell models. Drug interactions were evaluated using cell viability and colony formation assays. Homologous recombination activity was assessed using RAD51 foci formation and DR-GFP reporter assays. DNA damage, cell cycle distribution, and apoptosis were analysed using immunoﬂuorescence and ﬂow cytometry. Antitumour efﬁcacy was evaluated in xenograft models. Immune recognition-related features and susceptibility to CD8 + T-cell-mediated killing in vitro were assessed using peripheral blood mononuclear cell (PBMC) coculture assays. Results: Proteasome inhibitors emerged as the most consistent sensitising drug class. The oral proteasome inhibitor ixazomib citrate demonstrated robust synergy with olaparib across multiple HRP ovarian cancer models. Mechanistically, ixazomib citrate disrupted recruitment of the homologous recombination protein RAD51 to DNA damage sites without reducing its expression, thereby inducing a functional HRD-like state consistent with BRCAness. This disruption increased olaparib-induced DNA damage, resulting in G2/M arrest and apoptosis. In xenograft models, combination therapy signiﬁcantly suppressed tumour growth compared with either agent alone. Proteasome inhibition also increased tumour-surface MHC class I expression and appeared to enhance susceptibi","cbCaihKFlVirrAeG","https://ap.wps.com/l/cbCaihKFlVirrAeG","pdf",4228028,11,"English","# Background\n# Methods\n# Results\n# Conclusions\n# Introduction","[{\"question\":\"Why is PARP inhibitor therapy limited in HRP ovarian cancer?\",\"answer\":\"Approximately half of high-grade serous ovarian cancers retain intact homologous recombination repair and are classified as HRP, which limits the clinical benefit of PARPi in this population.\"},{\"question\":\"What was the key finding of the drug repurposing screen?\",\"answer\":\"Proteasome inhibitors emerged as the most consistent sensitising drug class, and ixazomib citrate showed robust synergy with olaparib across multiple HRP ovarian cancer models.\"},{\"question\":\"How does ixazomib citrate sensitize HRP models to PARP inhibition?\",\"answer\":\"Ixazomib citrate disrupted RAD51 recruitment to DNA damage sites without reducing RAD51 expression, inducing a functional HRD-like state that increases olaparib-induced DNA damage, leading to G2/M arrest and apoptosis.\"}]","Proteasome inhibition induces a BRCAness-like state and sensitises HR-proficient ovarian cancer models to PARP inhibitors | PDF",1790110499,28,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/34717641c79951a00233371c05621bda.webp",983,1389,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7e691555368b813b1f5d1b064039379d.webp",982,1388,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/68f4ad21c9fa1d7d08fc195c944b25cf.webp",981,1386,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d421996dc31253718811779f01fbcbd8.webp",980,1385]